Medicare Rx Plan Negotiations Will Avert Drug Industry "Windfall" – PhRMA
This article was originally published in The Pink Sheet Daily
Executive Summary
The industry group disputes predictions that the 2006 transfer of "dual eligibles" to Medicare will significantly benefit drug makers as Medicaid "best price" requirements no longer apply. However, states may lose price negotiating power, PhRMA says.
You may also be interested in...
Rx Depot Signs Consent Decree Admitting Liability For Importation
The firm and its corporate officers agree to permanently cease operations involving the illegal importation of prescription drugs. Rx Depot has been under a preliminary injunction since November 2003.
Medicare Rx Sponsors, States May Partner For Enhanced Drug Pricing Power
Medicaid programs and Medicare prescription drug plans will both be exempt from "best price" restrictions, providing an opportunity to negotiate drug prices together, Maine legislator says.
Endo’s Lidoderm Mailings Draw FDA Warning Letter For Unsubstantiated Claims
FDA asks Endo to disseminate “corrective messages” to doctors who received the violative promotional materials, which the agency says omit risk information and contain unsubstantiated effectiveness claims.